Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Detailed Status

Completed2

Active, not recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

active_not_recruiting125%

completed250%

terminated125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_1

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

NCT02721459

completedphase_1

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

NCT03095781

completedphase_1

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

NCT01657591

terminatedphase_1

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

NCT00796484

Clinical Trials (4)

Showing 4 of 4 trials

NCT02721459Phase 1

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Active Not Recruiting

NCT03095781Phase 1

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Completed

NCT01657591Phase 1

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Completed

NCT00796484Phase 1

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4